The Medical News

COVID-19 exposes deep-rooted structural inequities affecting vaccine uptake among ACB groups

The influence of poor vaccination uptake among African, Caribbean, and Black (ACB) communities.

The influence of poor vaccination uptake among African, Caribbean, and Black (ACB) communities.

1 year 1 month ago

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

FDA approves new dermal filler for hollows in upper face

The US Food and Drug Administration (FDA) has approved hyaluronic acid dermal filler, Juvederm Voluma XC for use in upper face for first time. The new dermal filler by Allergan Aesthetics' shall help improve moderate to severe temple hollows in adult patients aged 21 years and older.

JUVEDERM VOLUMA XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.

"The approval of JUVEDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie. "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."

JUVEDERM® VOLUMA® XC temporarily adds volume to immediately lift and augment the shape, contour, and structure of the temple, creating a smooth transition from the cheekbone to the forehead, balancing a patient's overall facial shape. In a clinical study, more than 80% of subjects had at least a one-point improvement in moderate to severe temple hollowing three months after treatment, and the improvement lasted for more than one year (73%). Additionally, more than 85% of clinical trial subjects were satisfied with how balanced, well-proportioned, and symmetric their face looked three months after treatment.

In the clinical study, 68% of subjects reported satisfaction with how fresh their face looked, while 73% reported satisfaction with how rested their face appeared three months after treatment. Additionally, upwards of 80% of subjects were satisfied with how youthful their temples made them look and how well the shape of their temples complemented the shape of their face three months after treatment. With this addition, the Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

"As an AMI trainer, I am excited to start training injectors on how to use JUVEDERM® VOLUMA® XC to help address moderate to severe temple hollowing while reinforcing how treatment in this important area fits into a full-face approach that enhances facial balance (framing) and contour for my patients seeking subtle improvement," said Dr. Deirdre Hooper, board-certified dermatologist at Audubon Dermatology, and clinical trial investigator. "In the clinical study, we found that patients said they looked an average of five years younger six months after JUVEDERM® VOLUMA® XC treatment. Additionally, more than 85% of clinical study participants were satisfied with the treatment and would recommend it to a friend more than one year after treatment. Once training is completed, injectors like me will be able to offer patients true pan-facial assessments and treatments for safe, repeatable, and optimal results using the Allergan Aesthetics portfolio of products."

Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and considerations for patient selection, safe injection in this area, as well as identification and management of potential complications. Successful completion of this training is necessary prior to the administration of JUVEDERM® VOLUMA® XC, and as such, Allergan Aesthetics anticipates that treatment in the temples with JUVEDERM® VOLUMA® XC will be available towards the end of this year.

In a randomized, controlled, multicenter clinical study to evaluate the safety and effectiveness of JUVEDERM® VOLUMA® XC for correction of temple hollowing, 112 subjects were randomized to a treatment group and received injections in the temple area during the primary phase of the study; 58 subjects were randomized to a no-treatment control group.1 Touch-up treatments occurred approximately 30 days after initial injection, if needed.1 After the three-month blinded "no treatment" control period, control subjects were offered treatment; 53 control subjects elected to receive treatment.  A total of 40 treatment-group subjects opted for the optional maintenance treatment, which was offered to the treatment group 13 months after the last treatment.

Subjects used electronic diaries to record specific signs and symptoms of treatment site responses (TSR) experienced during the first 14 days after the initial touch-up and maintenance treatments. Subjects in the initial treatment group continued to use the electronic diary on even-numbered days from day 16 to day 30 to record specific signs and symptoms of TSRs. Subjects rated each TSR listed on the diary as "Mild (barely noticeable)," "Moderate (uncomfortable)," "Severe (severe discomfort)," or "None."

After initial treatment with JUVEDERM® VOLUMA® XC, 59% of the subjects with diary entries reported experiencing at least one TSR and 70.5% of subjects rated TSRs as mild or moderate (26.3%) in severity, with a majority (60%) of all reported TSRs resolving within three days. The incidence of TSRs for the touch-up and maintenance treatments was lower than that for initial treatment.

JUVEDERM® VOLUMA® XC, one of six specifically designed products in the JUVÉDERM® Collection of Fillers, is currently also indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume loss in the mid-face, and for augmentation of the chin region to improve the chin profile.

1 year 1 month ago

Dermatology,Dermatology News,Top Medical News,Latest Medical News

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

WHO warns of growing resistance to GSK HIV drug

The World Health Organization (WHO) has said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries.

Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.HIV medicines reduce the amount of the virus in the body to a very low level and helps prevent illness."The resistance analysis focuses on subgroups whose virus was not suppressed and the data does not indicate that resistance was prevalent in the overall population", a GSK spokesperson said on Tuesday.The global health agency did not disclose the number of countries from where the data was reported, but said only a few countries have reported survey data to WHO, to date.Only Haiti reported survey data to the WHO for HIV drug resistance among infants who have not received the therapy or infants starting it.The WHO said there have been cases of resistance to a class of HIV drugs known as integrase-strand transfer inhibitors in patients who took the injectible version of an HIV preventive drug called cabotegravir or CAB-LA.Cabotegravir, also made by GSK, is sold under the brand name Apretude.The WHO recommended that countries routinely implement standardized surveillance of resistance to HIV drugs, which could help understand the patterns of resistance among people not achieving a suppressed viral load."We agree with the WHO that there is a need for further surveillance," GSK said.The agency has been recommending the use of dolutegravir as the preferred first- and second-line HIV treatment for all population groups since 2018.It has recommended use of long-acting injectable cabotegravir as an additional prevention for those at substantial risk of HIV infection since 2022.

Read also: GSK CEO Emma Walmsley total remuneration rises 51 percent to USD 16 million in 2023

1 year 1 month ago

News,Medicine,Medicine News,Industry,Pharma News,Latest Industry News

Health

Four ways to improve relationships

IN ANY relationship, there are inevitable challenges that arise. In these moments, our egos typically compel us to believe it is the other person in the dynamic who needs to change, say they were wrong, and apologise. But we can change this...

IN ANY relationship, there are inevitable challenges that arise. In these moments, our egos typically compel us to believe it is the other person in the dynamic who needs to change, say they were wrong, and apologise. But we can change this...

1 year 1 month ago

Health

An MPowered battle with fear

MEDICAL DISPOSABLES and Supplies Limited (MDS) recently held its 5th Annual MPowered Continuing Education Seminar for Pharmacists under the theme ‘Fearless’. With the support of the wider Caribbean community of pharmacists, MDS is the first...

MEDICAL DISPOSABLES and Supplies Limited (MDS) recently held its 5th Annual MPowered Continuing Education Seminar for Pharmacists under the theme ‘Fearless’. With the support of the wider Caribbean community of pharmacists, MDS is the first...

1 year 1 month ago

PAHO/WHO | Pan American Health Organization

Wave of new commitments marks historic step towards the elimination of cervical cancer

Wave of new commitments marks historic step towards the elimination of cervical cancer

Cristina Mitchell

5 Mar 2024

Wave of new commitments marks historic step towards the elimination of cervical cancer

Cristina Mitchell

5 Mar 2024

1 year 1 month ago

Health – Dominican Today

Dominican Republic issues Dengue alert amid regional increase

Santo Domingo.- The Dominican Republic’s Ministry of Public Health issued a new epidemiological alert for dengue on Monday, responding to an uptick in cases across the Americas region. In 2023, the region experienced its most severe year for the disease, with over 4.5 million people affected and 2,340 deaths.

Santo Domingo.- The Dominican Republic’s Ministry of Public Health issued a new epidemiological alert for dengue on Monday, responding to an uptick in cases across the Americas region. In 2023, the region experienced its most severe year for the disease, with over 4.5 million people affected and 2,340 deaths.

Despite a sustained decline in dengue cases in the country over the last 22 weeks, there is concern that the situation could change in 2024 due to significant global climate changes. Consequently, the ministry declared an epidemiological alert, recommending the implementation of strategies to control the Aedes aegypti mosquito, which reduces the transmission of the dengue virus, and the reinforcement of epidemiological surveillance.

The alert also calls for the establishment of a rapid response mechanism and the assurance of quality care for individuals with dengue. This decision comes as 3,889 suspected cases of dengue were reported in the first five weeks of the year.

Dengue incidence typically rises during the summer months, coinciding with the most humid season in the Caribbean. This favorable environment facilitates the proliferation of the Aedes aegypti mosquito, which also carries other diseases such as chikungunya and Zika.

Recalling the epidemic outbreak of dengue in the Dominican Republic last year, which saw 27,972 confirmed cases and 34 deaths, the ministry is taking proactive measures to address the potential risks in the current year.

Source: EFE

1 year 1 month ago

Health

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

NMC Invites Applications for Eligibility Certificate for FMGE, details

New Delhi: Through a recent notice, the Ethics and Medical Registration Board (EMRB) of the National Medical Commission (NMC) has invited applications for Eligibility Certificates, which are mandatory for foreign medical graduates to appear in the screening test i.e. Foreign Medical Graduates Examination (FMGE).

As per the EMRB notice dated 04.03.2024, the online submission of the application has started from today i.e. 5th March, 2024 onwards (09:00 AM onwards). The last date for submission of the application is 30th April, 2024, till 06:00 PM. 

The candidates requiring the Eligibility Certificate have been requested to apply through the NMC website within 30.04.2024.

Mentioning that the FMGE Screening Test is tentatively scheduled to be conducted in June 2024 by the National Board of Examinations in Medical Sciences (NBEMS), NMC further clarified that "As per the requirements, the candidates who are required to have the eligibility certificate are not permitted to apply for the Screening Test without the Eligibility Certificate issued by the National Medical Commission."

"The requirement of the Eligibility Certificate may be confirmed by referring to the public notice dated 11.12.2018, 05.04.2019 & 22.11.2023 from the NMC website," NMC mentioned in the notice, issued by EMRB member Dr. Vijaya Lakshmi Nag.

"All such candidates who intend to correspond regarding their applications are requested to provide a reference of their file Tracking No." it added.

NMC has also issued an advisory regarding the eligibility certificate for the FMGs. Referring to the mistakes by the candidates while applying for Eligibility Certificates, the Ethics Board of NMC mentioned in the Advisory, "It has also been observed on previous occasions that various mistakes are made by the candidates while applying for the Eligibility Certificate (EC)."

The Commission suggested the following measures to avoid mistakes:

(i) The applications should preferably be filled by the candidate himself and should ideally avoid proxy for making applications for EC:

(ii) The candidates are also advised to keep their documents handy before filling application for EC; it would be ideal if the entries to be made are verified vis-a-vis entries in the original documents;

(iii) The candidates should provide their active mobile numbers so that alerts/deficiencies can reach them directly for rectification to obviate any delay in rectification. It may also be ensured that once the deficiency is conveyed only the deficiency should be rectified by the respective candidate as expeditiously as possible to avoid last minute rush; and

(iv) Candidates shall scrupulously check entries and ensure conformity with the details in the original documents to ensure quick processing/approval of applications if otherwise eligible.

"The above-mentioned steps are only suggestive and not exhaustive. Candidates are requested to exercise due diligence before submitting applications for Eligibility Certificates and ensure the mobile numbers indicated remain active," the Commission clarified.

Medical Dialogues had earlier reported that despite completing all the required procedures in this regard, several candidates were facing problems in obtaining the mandatory eligibility certificate from the Apex Medical Commission. Even the FMGs who applied in 2021, 2022, and earlier months of 2023 were facing the problem.

Their applications were pending at some level and they were not getting the certificates. Therefore, they were missing their chances to appear in the FMGE test.

Previously, the Union Minister of State for Health, Dr. Bharati Pravin Pawar addressed the issue of FMGs and informed the Lok Sabha that the delay in issuing eligibility certificates to the FMGs occurs due to delay in the validation of documents submitted by the candidates, verification of admission letter from the foreign medical institutions.

To view the NMC notice, click on the link below:

https://medicaldialogues.in/pdf_upload/nmc-portal-eligibility-certificate-233649.pdf

To view the NMC Advisory, click on the link below:

https://medicaldialogues.in/pdf_upload/nmc-advisory-eligibility-certificate-233650.pdf

Also Read: Pending Eligibility Certificates: NMC Releases List of 119 FMGs, Gives Deadline to Submit Applications

1 year 1 month ago

State News,News,Health news,Delhi,Doctor News,NMC News,Medical Education,Top Medical Education News,Notifications,Latest Education News

NYT > Health

Apparently Healthy, but Diagnosed With Alzheimer’s?

New criteria could lead to a dementia diagnosis on the basis of a simple blood test, even in the absence of obvious symptoms.

New criteria could lead to a dementia diagnosis on the basis of a simple blood test, even in the absence of obvious symptoms.

1 year 1 month ago

Tests (Medical), Alzheimer's Disease, Drugs (Pharmaceuticals), Conflicts of Interest, Dementia, Brain, Blood, Elderly, Memory, Research

PAHO/WHO | Pan American Health Organization

World Obesity Day: PAHO launches Creative Play Initiative in Barbados schools

World Obesity Day: PAHO launches Creative Play Initiative in Barbados schools

Oscar Reyes

4 Mar 2024

World Obesity Day: PAHO launches Creative Play Initiative in Barbados schools

Oscar Reyes

4 Mar 2024

1 year 1 month ago

Health | NOW Grenada

What is chronic kidney failure?

“Chronic Kidney Disease or renal failure occurs when one or both kidneys are unable to perform their duties adequately”

View the full post What is chronic kidney failure? on NOW Grenada.

“Chronic Kidney Disease or renal failure occurs when one or both kidneys are unable to perform their duties adequately”

View the full post What is chronic kidney failure? on NOW Grenada.

1 year 1 month ago

Health, PRESS RELEASE, chronic kidney disease, grenada food and nutrition council, renal failure

Health | NOW Grenada

If crime is not a national disaster, I don’t know what is!!

“From Haiti in the north to Trinidad & Tobago in the south, the Homicidal Hurricane punched a whopping 7,064 deaths in 2023, with the greater percentage of fatalities being that of young men”

1 year 1 month ago

Community, Crime, Health, OPINION/COMMENTARY, Youth, gabrielle hosein, homicide, neals chitan, Public Health, tracey mcveigh, uk guardian

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

AbbVie, OSE Immunotherapeutics collaborate to develop novel monoclonal antibody for Chronic Inflammation

North Chicago, Ill.: AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, have announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for the resolution of chronic inflammation, modulating functions of both macrophages and neutrophils.

"This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation."

"We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward," said Nicolas Poirier, chief executive officer, OSE Immunotherapeutics. "This partnership represents a major milestone in our company's progress and recognizes the value of our innovative R&D capabilities. I would like to thank all our employees who helped us reach this milestone through dedication and hard work."

Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive a $48 million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. In addition, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230.

The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Read also: AbbVie, Tentarix collaborate to develop conditionally-active, multi-specific biologics for oncology, immunology

1 year 1 month ago

News,Industry,Pharma News,Latest Industry News

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Johnson and Johnson gets USFDA approval for Rybrevant, chemotherapy combo for lung cancer treatment

Raritan: Johnson & Johnson has announced that following a priority review, the U.S.

Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.

 This FDA action converts the May 2021 accelerated approval of RYBREVANT to a full approval based on the confirmatory Phase 3 PAPILLON study.

“When aiming for the best possible treatment outcomes, a targeted approach should be used in the first line for patients with EGFR exon 20 insertion mutations, as this is a commonly applied practice for patients with NSCLC harboring other molecular driver alterations,” said Joshua K. Sabari, M.D., an oncologist at NYU Langone’s Perlmutter Cancer Center and study investigator. “The results observed in the PAPILLON study showed significant improvement in progression-free survival, supporting the use of this regimen as the potential standard-of-care in the first-line treatment of these patients.”

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases. Alterations in EGFR are the most common actionable driver mutations in NSCLC. Clinical data show patients with EGFR exon 20 insertion mutations generally experience limited benefits with currently approved third-generation EGFR tyrosine kinase inhibitors and chemotherapy. NSCLC driven by EGFR exon 20 insertion mutations carries a worse prognosis and shorter survival rates compared with lung cancer driven by other EGFR driver mutations.

“For patients with lung cancer and their families, each breakthrough in treatment provides not only a new option, but a potential lifeline. The approval of RYBREVANT plus chemotherapy heralds a promising new first-line treatment option for patients newly diagnosed with non-small cell lung cancer where their driver mutation is an EGFR exon 20 insertion,” said Marcia Horn, Executive Director of the Exon 20 Group and CEO of ICAN, International Cancer Advocacy Network. “This new regimen is a major advance over chemotherapy alone. We’ve seen first-hand the extended survival that Exon 20 Group patients experienced on RYBREVANT plus chemotherapy in the PAPILLON study, and we’re delighted that this historic treatment option, which specifically targets the EGFR exon 20 insertion mutation, has been approved.”

The FDA approval is based on positive results from the randomized, open-label Phase 3 PAPILLON study, which showed RYBREVANT plus chemotherapy resulted in a 61 percent reduction in the risk of disease progression or death compared to chemotherapy alone. Results also showed treatment with RYBREVANT plus chemotherapy improved objective response rate (ORR) and progression-free survival (PFS). Based on PAPILLON data, the National Comprehensive Cancer Network (NCCN) updated its’ NCCN Clinical Practice Guidelines (NCCN Guidelines) to include a category 1 recommendation for amivantamab-vmjw (RYBREVANT) plus chemotherapy as a preferred first-line therapy for patients with NSCLC with EGFR exon 20 insertion mutations.8 †‡

“We are redefining care for patients with non-small cell lung cancer by advancing innovative regimens that can be used early, with the goal of extending survival,” said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumors, Johnson & Johnson Innovative Medicine. “RYBREVANT plus chemotherapy is the first targeted approach approved for the first-line treatment of patients with NSCLC with EGFR exon 20 insertion mutations. We look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio.”

Warnings and Precautions include Infusion Related Reactions (IRR), Interstitial Lung Disease (ILD)/Pneumonitis, Dermatologic Adverse Reactions, Ocular Toxicity and Embryo-fetal Toxicity. The most common adverse reactions (≥20 percent) were rash, nail toxicity, stomatitis, IRR, fatigue, edema, constipation, decreased appetite, nausea, COVID-19, diarrhea and vomiting. The most common Grade 3 or 4 laboratory abnormalities (≥2 percent) were decreased albumin, increased alanine aminotransferase, increased gamma-glutamyl transferase, decreased sodium, decreased potassium, decreased magnesium, and decreases in white blood cells, hemoglobin, neutrophils, platelets, and lymphocytes.

Read also: JnJ gets USFDA nod for Bi-weekly dose of blood cancer therapy Tecvayli

1 year 1 month ago

News,Oncology,Pulmonology,Oncology News,Pulmonology News,Industry,Pharma News,Latest Industry News

PAHO/WHO | Pan American Health Organization

One in eight people are now living with obesity

One in eight people are now living with obesity

Cristina Mitchell

1 Mar 2024

One in eight people are now living with obesity

Cristina Mitchell

1 Mar 2024

1 year 1 month ago

Healio News

Testosterone therapy does not slow progression to diabetes, increase odds for remission

Testosterone replacement therapy alone did not lower risk for progression from prediabetes to diabetes or increase the likelihood of type 2 diabetes remission among men with hypogonadism, according to study data.In the TRAVERSE trial, men aged 45 to 80 years with hypogonadism were randomly assigned, 1:1, to transdermal 1.62% testosterone gel (AbbVie) or placebo until the end of the study.

In findings from a substudy of the TRAVERSE trial published in JAMA Internal Medicine, researchers found testosterone therapy did not result in differences in glycemic outcomes compared with placebo.“The

1 year 1 month ago

Health – Dominican Today

DR and PAHO join forces to combat Dengue

Santo Domingo.- The Minister of Public Health, Víctor Atallah, held a meeting with Alba María Ropero Álvarez, the representative of the Pan American Health Organization (PAHO) for the Dominican Republic. The purpose of this meeting was to coordinate and formulate a strategic plan for the prevention and control of dengue.

Santo Domingo.- The Minister of Public Health, Víctor Atallah, held a meeting with Alba María Ropero Álvarez, the representative of the Pan American Health Organization (PAHO) for the Dominican Republic. The purpose of this meeting was to coordinate and formulate a strategic plan for the prevention and control of dengue.

This meeting is part of the ongoing collaborative efforts between both entities, where plans are systematically developed to combat and prevent the spread of the disease within the Dominican Republic.

The collaboration agreement stems from a request by the Ministry of Health to the World Health Organization (WHO), seeking support from this international entity in the prevention and control of dengue—a vector-borne disease that has significantly impacted the region.

In response, both the Ministry of Health and PAHO recognized the urgency of establishing a collective health program management group, focusing on the most affected provinces. This group will be responsible for continuous monitoring and evaluation of the action plan to eliminate dengue vectors.

PAHO has also committed to providing technical cooperation support to enhance services, including training personnel at all levels of care, including the private sector. This involves the visit of international experts in the Management of Arbovirosis Clinic (RENACAR), with an official launch scheduled for March 2024.

Furthermore, the agreement includes the development and launch of an entomological survey application, educational campaigns in schools, community dialogues, and empowerment initiatives through various educational and communication programs.

The Vice Minister of Collective Health, Eladio Pérez, and the Director of Prevention and Promotion, Dr. Miguel Brujan, were also present at the meeting. They emphasized the need for regional epidemiological training workshops to address the new dengue surveillance protocol, considering that the disease’s behavior, influenced by climatic factors, deviates from regular epidemiological patterns.

Minister Atallah reaffirmed the commitment to the health and well-being of all Dominicans and expressed gratitude to PAHO/WHO for its ongoing support in these critical initiatives. The coordinated efforts aim for an effective and sustained response against dengue.

1 year 1 month ago

Health

KFF Health News

KFF Health News' 'What the Health?': Alabama’s IVF Ruling Still Making Waves

The Host

Julie Rovner
KFF Health News


@jrovner


Read Julie's stories.

The Host

Julie Rovner
KFF Health News


@jrovner


Read Julie's stories.

Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to Z,” now in its third edition.

Reverberations from the Alabama Supreme Court’s first-in-the-nation ruling that embryos are legally children continued this week, both in the states and in Washington. As Alabama lawmakers scrambled to find a way to protect in vitro fertilization services without directly denying the “personhood” of embryos, lawmakers in Florida postponed a vote on the state’s own “personhood” law. And in Washington, Republicans worked to find a way to satisfy two factions of their base: those who support IVF and those who believe embryos deserve full legal rights.

Meanwhile, Congress may finally be nearing a funding deal for the fiscal year that began Oct. 1. And while a few bipartisan health bills may catch a ride on the overall spending bill, several other priorities, including an overhaul of the pharmacy benefit manager industry, failed to make the cut.

This week’s panelists are Julie Rovner of KFF Health News, Rachel Cohrs of Stat, Riley Griffin of Bloomberg News, and Joanne Kenen of Johns Hopkins University’s schools of nursing and public health and Politico Magazine.

Panelists

Rachel Cohrs
Stat News


@rachelcohrs


Read Rachel's stories.

Riley Griffin
Bloomberg


@rileyraygriffin


Read Riley's stories.

Joanne Kenen
Johns Hopkins Bloomberg School of Public Health and Politico


@JoanneKenen


Read Joanne's articles.

Among the takeaways from this week’s episode:

  • Lawmakers are readying short-term deals to keep the government funded and running for at least a few more weeks, though some health priorities like preparing for a future pandemic and keeping down prescription drug prices may not make the cut.
  • After the Alabama Supreme Court’s decision that frozen embryos are people, Republicans find themselves divided over the future of IVF. The emotionally charged debate over the procedure — which many conservatives, including former Vice President Mike Pence, believe should remain available — is causing turmoil for the party. And Democrats will no doubt keep reminding voters about it, highlighting the repercussions of the conservative push into reproductive health care.
  • A significant number of physicians in Idaho are leaving the state or the field of reproductive care entirely because of its strict abortion ban. With many hospitals struggling with the cost of labor and delivery services, the ban is only making it harder for women in some areas to get care before, during, and after childbirth — whether they need abortion care or not.
  • A major cyberattack targeting the personal information of patients enrolled in a health plan owned by UnitedHealth Group is drawing attention to the heightened risks of consolidation in health care. Meanwhile, the Justice Department is separately investigating UnitedHealth for possible antitrust violations.
  • “This Week in Health misinformation”: Panelist Joanne Kenen explains how efforts to prevent wrong information about a new vaccine for RSV have been less than successful.

Also this week, Rovner interviews Greer Donley, an associate professor at the University of Pittsburgh School of Law, about how a 150-year-old anti-vice law that’s still on the books could be used to ban abortion nationwide.

Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:

Julie Rovner: ProPublica’s “Their States Banned Abortion. Doctors Now Say They Can’t Give Women Potential Lifesaving Care,” by Kavitha Surana.

Rachel Cohrs: The New York Times’ “$1 Billion Donation Will Provide Free Tuition at a Bronx Medical School,” by Joseph Goldstein.

Joanne Kenen: Axios’ “An Unexpected Finding Suggests Full Moons May Actually Be Tough on Hospitals,” by Tina Reed.

Riley Griffin: Bloomberg News’ “US Seeks to Limit China’s Access to Americans’ Personal Data,” by Riley Griffin and Mackenzie Hawkins.

Also mentioned on this week’s podcast:

click to open the transcript

Transcript: Alabama’s IVF Ruling Still Making Waves

KFF Health News’ ‘What the Health?’Episode Title: Alabama’s IVF Ruling Still Making WavesEpisode Number: 336Published: Feb. 29, 2024

[Editor’s note: This transcript was generated using both transcription software and a human’s light touch. It has been edited for style and clarity.]

Julie Rovner: Hello, and welcome back to “What the Health?” I’m Julie Rovner, chief Washington correspondent for KFF Health News, and I’m joined by some of the best and smartest health reporters in Washington. We’re taping this week on Thursday, Feb. 29, at 10 a.m. Happy leap day, everyone. As always, news happens fast and things might’ve changed by the time you hear this, so here we go.

We are joined today via video conference by Rachel Cohrs of Stat News.

Rachel Cohrs: Hi, everybody.

Rovner: Riley Ray Griffin of Bloomberg News.

Riley Griffin: Hello, hello.

Rovner: And Joanne Kenen of the Johns Hopkins University schools of nursing and public health and Politico Magazine.

Joanne Kenen: Hi, everybody.

Rovner: Later in this episode we’ll have my interview with University of Pittsburgh law professor Greer Donley about that 150-year-old Comstock Act we’ve talked about so much lately. But first, this week’s news.

So as we tape this morning, the latest in a series of short-term spending bills for the fiscal year that began almost five months ago, is a day and a half away from expiring, and the short-term bill for the rest of the government is 15 days from expiring. And apparently the House and Senate are in the process of preparing yet another pair of short-term bills to keep the government open for another week each, making the new deadlines March 8 and March 22. I should point out that the Food and Drug Administration is included in the first set of spending bills that would expire, and the rest of HHS [Department of Health and Human Services] is in the second batch.

So what are the chances that this time Congress can finish up the spending bills for fiscal 2024? Rachel, I call this Groundhog Day, except February’s about to be over.

Cohrs: Yeah, it’s definitely looking better. I think this is the CR [continuing resolution] where, as I’m thinking about it, the adults are in the room and the negotiations are actually happening. Because we had a couple of fake-outs there, where nobody was really taking it seriously, but I think we are finally at a place where they do have some agreement on some spending bills. The House hopefully will be passing some of them, and I’m optimistic that they’ll get it at least close within that March 8-March 22 time frame to extend us out a few more months until we get to do this all over again in September.

At least right now, which it could change, they do have a couple of weeks, but it’s looking like the main kind of health care provisions that we were looking at are going to be more of an end-of-year conversation than happening this spring.

Rovner: Which is anticipating my next question, which is a bunch of smaller bipartisan bills that were expected to catch a ride on the spending bill train seemed to have been jettisoned because lawmakers couldn’t reach agreement. Although it does look like a handful will make it to the president’s desk in this next round, and its last round, of fiscal spending bills for fiscal 2024.

Let’s start with the bills that are expected to be included when we finally get to these spending bills, presumably in March.

Cohrs: So, from my reporting, it sounds like that there’s going to be an extension of funding for the really truly urgent programs that are expiring. We’re talking community health center funding, funding for some public health programs. It’s funding for safety-net hospitals through Medicaid. Those policies might be extended. There’s a chance that there could be some bump in Medicare payments for doctors. I haven’t seen a final number on that yet, but that’s at least in the conversation for this round.

Again, there’s going to be more cuts at the end of this year. So, I think we’ll be continuing to have this conversation, but those look like they’re in for now. Again, we don’t have final numbers, but that’s kind of what we’re expecting the package to look like.

Kenen: And the opioids is under what you described as public health, right, or is that still up in the air?

Cohrs: I think we’re talking SUPPORT Act; I think that is up in the air, from my understanding. With public health programs talking, like, special diabetes reauthorization — there are a couple more small-ball things, but I think SUPPORT Act, PAHPA [Pandemic and All Hazards Preparedness Act], to my understanding, are still up in the air. We’ll just have to wait for text. That hopefully comes soon.

Rovner: Riley, I see you nodding too. Is that what you’re hearing?

Griffin: Yeah. Questions about PAHPA, the authorizations for pandemic and emergency response activities, have been front of mind for folks for months and months, particularly given the timing, right? We are seeing this expire at a time when we’ve left the biggest health crisis of our generation, and seeing that punted further down the road I think will come as a big disappointment to the world of pandemic preparedness and biodefense, but perhaps not altogether unexpected.

Rovner: So Rachel, I know there were some sort of bigger things that clearly got left on the cutting room floor, like legislation to do something about pharmacy benefit managers and site-neutral payments in Medicare. Those are, at least for the moment, shelved, right?

Cohrs: Yes. That’s from my understanding. Again, I will say now they bought themselves a couple more weeks, so who knows? Sometimes a near-death experience is what it takes to get people moving in this town. But the most recent information I have is that site-neutral payments for administering drugs in physicians’ offices, that has been shelved until the end of the year and then also reforms to how PBMs [pharmacy benefit managers] operate. There’s just a lot of different policies floating around and a lot of different committees and they just didn’t come to the table and hash it out in time. And I think leadership just lost patience with them.

They do see that there’s another bite at the apple at the end of the year. We do have a lot of members retiring, Cathy McMorris Rodgers on the House side, maybe [Sen.] Bernie Sanders. He has not announced he’s running for reelection yet. So I think that’s something to keep in mind for the end of the year. And there also is a big telehealth reauthorization coming up, so I think they view that as a wildly popular policy that’s going to be really expensive and it’s going to be another … give them some more time to just hash out these differences.

Kenen: I would also point out that this annual fight about Medicare doctor payments was something that was supposedly permanently fixed. Julie and I spent, and many other reporters, spent countless hours staking out hallways in Congress about this obscure thing that was called SGR, the sustainable growth rate, but everyone called it the “doc fix.” It was this fight every year that went on and on and on about Medicare rates and then they replaced it and it was supposed to be, “We will never have to deal with this again.”

I decided I would never write another story about it after the best headline I ever wrote, which was, “What’s up, doc fix?” But here we are again. Every single year, there’s a fight about …

Rovner: Although this isn’t the SGR, it’s just …

Kenen: They got rid of SGR, that era was over. But what we’ve learned is that era will probably never be over. Every single year, there will be a lobbying blitz and a fight about Medicare Advantage and about Medicare physician pay. It’s like leap year, but it happens every year instead of every four.

Rovner: Because lobbyists need to get paid too.

All right, well, I want to turn to abortion where the fallout continues from that Alabama Supreme Court ruling earlier this month that found frozen embryos are legally children. Republicans, in particular, are caught in an almost impossible position between portions of their base who genuinely believe that a fertilized egg is a unique new person deserving of full legal rights and protections, and those who oppose abortion but believe that discarding unused embryos as part of the in vitro fertilization process is a morally acceptable way for couples to have babies.

In Alabama, where the ruling has not just stopped IVF clinics from operating in the state, but has also made it impossible for those in the midst of an IVF cycle to take their embryos elsewhere because the companies that would transport them are also worried about liability, the Republican-dominated legislature is scrambling to find a way to allow IVF to resume in the state without directly contradicting the court’s ruling that “personhood” starts at fertilization.

This seems to be quite a tightrope. I mean, Riley, I see you nodding. Can they actually do this? Is there a solution on the table yet?

Griffin: No, I don’t think there’s a solution on the table yet, and there are eight clinics in Alabama that do this work, according to the CDC [Centers for Disease Control and Prevention]. Three of them have paused IVF treatment across the board. We’ve been in touch with these clinics as days go by as we see some of these developments, and they’re not changing their policies yet. Some of these efforts by Republicans to assure that there won’t be criminal penalties, they’re not reassuring them enough.

So, it certainly is a tightrope for providers and patients. It’s also a tightrope, as you mentioned, Julie, for the Republican Party, which is divided on this matter, and for Republican voters, who are also divided on this matter. But ultimately, this whole conversation comes back to what constitutes a human being? What constitutes a person? And the strategy of giving rights to an embryo allows abortion laws to be even more restrictive across this country.

Rovner: Yeah, I can’t tell you how many stories I’ve written about “When does life begin?” over the last 30 years, because that’s really what this comes down to. Does life begin at fertilization? Does it begin … I mean, doctors, I have learned this over the years, that conception is actually not fertilization. Conception is when basically a fertilized egg implants in a woman’s uterus. That’s when pregnancy begins. So there’s this continuing religious and scientific and ethical and kind of a quagmire that now is front and center again.

Joanne, you wanted to add something?

Kenen: No. I mean, I thought [Sen.] Lindsey Graham had one of the best quotes I’ve seen, which is, “Nobody’s ever been born in a freezer.” So this is a theological question that is turning into a political question. And even the proposed legislation in Alabama, which would give the clinics immunity or a pardon, I mean, pardon means you committed a crime. In this case, a murder, but you were pardoned for it. I mean, I don’t think that’s necessarily … and it’s only good for this was a stopgap that would, if it passes, I believe it would be just till early 2025.

So it might get these clinics open for a while. They may come up with some way of getting families that are in the middle of fertility treatments to be able to complete it, but other states could actually go the way Alabama went. We have no guarantee. There are people pushing for that in some of the more conservative states, so this may spread. The attempt in Congress, in the Senate, to bring up a bill that would address it …

Rovner: We’ll get to that in a second.

Kenen: I mean, Alabama’s a conservative state, but the governor, who was a conservative anti-abortion governor, has said she wants to reopen the clinics and protect them, but they haven’t come up with the formula to do that yet.

Rovner: So speaking of other states, when this decision came down in Alabama, Florida was preparing to pass its own personhood bill, but now that vote has been delayed at the request of the bill’s sponsor. The, I think, initial reaction to the Alabama decision was that it would spur similar action in other states, as you were just saying, Joanne, but is it possible that the opposite will happen, that it will stop action in other states because those who are pushing it are going to see that there’s a huge divide here?

Griffin: That hesitation certainly signals that that’s a possibility. The pause in pushing forward that path in Florida is a real signal that there is going to be more debate within the Republican Party.

One thing I do want to mention is a lot of focus has been on whether clinics in Alabama or otherwise would stop IVF treatment altogether. But I think equally important is how the clinics that are continuing to offer IVF treatment, what changes they’re making. The ones that we’re seeing, are speaking with in Alabama that are continuing to offer IVF, are changing their consent forms. They are fertilizing fewer eggs, they’re freezing eggs, but they’re not fertilizing them because they don’t want to have excess wastage, in their perspective, that could lead them to a place of liability.

So all these things ultimately have ramifications for patients. That is more costly. It means a longer timeline. It also means fewer shots on goal. It means that it is potentially harder for you to get pregnant, at the end of the day. So I want to center the fact that clinics that are continuing to offer IVF are facing real changes here too.

Rovner: We know from Texas that when states try to indemnify, saying, “Well, we won’t prosecute you,” that that’s really not good enough because doctors don’t want to run the chance of ending up in court, having to hire lawyers. I mean, even if they’re unlikely to be convicted and have their licenses taken away, just being charged is hard enough. And I think that’s what’s happening with doctors with some of these abortion exceptions, and that’s what’s happening with these IVF clinics in places where there’s personhood.

Sorry, Joanne. Go ahead.

Kenen: Egg-freezing technology has gotten better than it was just a few years ago, but egg-freezing technology, to the best of my knowledge, egg-freezing technology, though improved, is nowhere near as good as freezing an embryo. Particularly now they can bring embryos out to what they call the blastocyst stage. It’s about five days. They have a better chance of successful implantation.

In addition to the expense of IVF, and it’s expensive and most people don’t have insurance cover[age] for it, it means you’re going through drugs and treatment and all of us have had friends, I think, who’ve gone through it or relatives. It is just an incredibly stressful, emotionally painful process.

Rovner: Well, you’re pumping yourself full of hormones to create more eggs, so yeah.

Kenen: And you’re also trying to get pregnant. If you’re spending $20,000 a cycle or whatever it is, and pumping yourself full of hormones, doing all this, it means that having a child is of utmost importance to you.

And the emotional trauma of this, if you listen to the … we’ve heard interviews in the last few days of women who were about to have a transfer and things like that, the heartbreak is intense, and fertility is not like catching a cold. It’s really stressful and sad, and this is just causing anguish to families trying to have a child, trying to have a first child, trying to have a second child, whatever, or trying to have a child because there’s a health issue and they want to do the pre-implantation genetic testing so that they don’t have another child die. I mean, it’s really complicated and terrible costs on all kinds of costs, physical, emotional, and financial.

Rovner: Yeah, there are lots of layers to this.

Well, meanwhile, this decision has begun to have repercussions here on Capitol Hill. In the Senate, the Democrats are, again, while it’s in the news, trying to force Republicans into taking a stand on this issue by bringing up a bill that would guarantee nationwide access to IVF. This is a bill that they tried to bring up before and was blocked by Republicans. On Wednesday, a half a dozen senators led by Illinois’ Tammy Duckworth, a veteran who used IVF to have her two children, chided Republicans on the floor who failed again to let them bring up the IVF bill. This time, as last time, it was blocked by Republican Sen. Cindy Hyde-Smith of Mississippi.

I imagine the Democrats aren’t going to let this go anytime soon though. They certainly indicated that this is not their last attempt at this.

Kenen: No. Why should they? If anyone thought that the politics of abortion were going to subside by November, this has just given it … I don’t even have a word for how much it’s been reinvigorated. This is going to stick in people’s minds, and Republicans are divided on IVF, but there’s no path forward. Democrats are going to be trying again and again, if they can, and they’re going to remind voters of it again and again.

Rovner: And in the Republican House, they’re scrambling to figure out again, as in Alabama, how to demonstrate support for IVF without running afoul of their voters who are fetal personhood supporters.

Just to underline how delicate this all is, the personhood supporting anti-abortion group, Susan B. Anthony [Pro-Life America], put out a statement this week, not just thrashing the Democrats’ bill, which one would expect, but also the work going on by Republicans in Alabama and in the U.S. House for not going far enough. They point out that Louisiana has a law that allows for IVF, but not for the destruction of leftover embryos. Although that means, as Riley was saying before, those embryos have to be stored out of state, which adds to the already high cost of IVF.

It is really hard to imagine how Republicans at both the state and federal level are going to find their way out of this thicket.

Kenen: It’s a reproductive pretzel.

Griffin: It’s a reproductive pretzel where two-thirds of Americans say frozen embryos shouldn’t be considered people. So I mean, there is data to suggest that this isn’t a winning selling point for the Republican Party, and we saw that play out with presidential candidate Donald Trump immediately distancing himself from the Alabama Supreme Court decision. So, what a pretzel it is.

It’s going to be interesting to see how this pans out as the logistical hurdles continue to arise. And some are basic. I mean, I spoke last week with one clinic in Alabama that said that they had had dozens, I think they said 30 to 40, embryos that had been abandoned over decades going back as 2008, and they had tried to reach people by phone, by mail, by email. They had just been left behind. What do you do in that situation? They had been prepared to dispose of those embryos and now they’re sitting on shelves. Is that the answer? Is the only answer to have shelves and shelves of frozen embryos?

Rovner: Yeah, I mean, it is. It is definitely a pretzel.

Kenen: There was a move at one point to allow them to be adopted. I think …

Rovner: It’s still there. It’s still there.

Kenen: Right, but I don’t know what kind of consent you need. I mean, if the situations where someone left the frozen embryo and doesn’t respond or their email, they’ve changed their email or whatever, there may be some kind of way out for this mess that involves the possibility of adopting them at some point down the road, and they may not be biologically viable by that point. But when I was thinking of what are the political outs, what is the exit ramp, I haven’t heard any politicians talk about this yet, but that occurred to me as something that might end up figuring into this.

And the other thing, just to the point as to how deeply divided, I think many listeners know this, but for the handful who don’t, the illustration of how deeply divided even very anti-abortion Republicans are, is [former Vice President] Mike Pence, his family was created through IVF, and he’s clearly, he’s come out this week. I mean, there’s no question that Mike Pence is anti-abortion, there’s not a lot of doubt about that, but he has come forth and endorsed IVF as a life-affirming rather, as a good thing.

Rovner: And I actually went and checked when this all broke because Joanne probably remembers in the mid-2000s when they were talking about stem cell research that President George W. Bush had a big event with what were called “snowflake children,” which were children who were born because they were adopted leftover embryos that someone else basically gestated, and that …

Kenen: But I don’t think they’ll call them “snowflake” anymore.

Rovner: Yeah. Well, that adoption agency is still around and still working and still accepting leftover embryos to be adopted out. That does still exist. I imagine that’s probably of use in Louisiana too, where you’re not allowed to destroy leftover embryos.

Well, meanwhile, we have some new numbers on something else we’ve been talking about since Dobbs [v. Jackson Women’s Health Organization]. Doctors who deliver babies in states with abortion bans are choosing to leave rather than to risk arrest or fines for providing what they consider evidence-based care. In Idaho, according to a new report, 22% of practicing obstetricians stopped practicing or left the state from August 2022 to November 2023. And, at the same time, two hospitals’ obstetric programs in the state closed, while two others report having trouble recruiting enough doctors to keep their doors open.

I would think this is going to particularly impact more sparsely populated states like Idaho, which also, coincidentally or not, are the states that tend to have the strictest abortion bans. I mean, it’s going to be … this seems to be another case where it’s going to be harder, where abortion bans are going to make it harder to have babies.

Cohrs: Yeah. I mean, we’re already seeing a trend of hospital systems being reluctant to keep OB-GYN delivery units open anyway. We’ve seen care deserts. It’s really not a profitable endeavor unless you have a NICU [neonatal intensive care unit] attached. So I think this just really compounds the problems that we’ve been hearing about staffing, about rural health in general, recruiting, and just makes it one step harder for those departments that are really important for women to get the care they need as they’re giving birth, and just making sure that they’re safe and well-staffed for those appointments leading up to and following the birth as well.

Kenen: Right. And at a time we’re supposedly making maternal mortality a national health priority, right? So you can’t really protect women at risk, and, as Rachel said, it’s during childbirth, but it’s for months after. And without proper care, we are not going to be able to either bring down the overall maternal mortality rates nor close the racial disparities.

Griffin: I was just going to say, I highly recommend a story the New Yorker did this past January, “Did an Abortion Ban Cost a Young Texas Woman Her Life?” It’s a view into many of these different themes and will show you a real human story, a tragic one at that, about what these deserts, how they have consequential impact on people’s lives for both mother and baby.

Rovner: Yeah, and we talked about that when it came out. So if you go back, if you scroll back, you’ll find a link to it in the show notes.

I was going to say March is when we get “Match Day,” which is when graduating medical students find out where they’re going to be completing their training. And we saw just sort of the beginnings last year of kind of a dip in graduating medical students who want to become OB-GYNs who are applying to programs in states with abortion bans. I’ll be really curious this year to see whether that was a statistical anomaly or whether really people who want to train to be OB-GYNs don’t want to train in states where they’re really worried about changing laws.

We have to move on. I want to talk about something I’m calling the most under-covered health story of the month, a huge cyberattack on a company called Change Healthcare, which is owned by health industry giant UnitedHealth [Group]. Change processes insurance claims and pharmacy requests for more than 300,000 physicians and 60,000 pharmacies. And as of Wednesday, its systems were still down a week after the attack.

Rachel, I feel like this is a giant flashing red light of what’s at risk with gigantic consolidation in the health care industry. Am I wrong?

Cohrs: You’re right, which is why a couple of my colleagues did cover it as just this important red flag. And there are new SEC [Securities and Exchange Commission] reporting rules as well that require more disclosure around these kind of events. So I think that will …

Rovner: Around the cyberattacks?

Cohrs: Yes, around the cyberattacks, yes. But I think just the idea that, we’ll talk about this later too, but that Change is owned by UnitedHealth and just so much is consolidated that it really does create risks when there are vulnerabilities in these very essential processes. And I think a lot of people just don’t understand how many health care companies, they don’t provide any actual care. They’re just helping with the backroom kind of operations. And when you get these huge conglomerates or services that are bundled together under one umbrella, then it really does show you how a very small company maybe not everyone had heard of before this week could take down operations when you go to your pharmacy, when you go to your doctor’s office.

Rovner: Yeah, and there are doctors who aren’t getting paid. I mean, there’s bills that aren’t getting processed. Everything was done through the mail and it was slow and everybody said, “When we digitize it, it’s all going to be better and it’s all going to happen instantly.” And mostly what it’s done is it’s created all these other companies who are now making money off the health care system, and it’s why health care is a fifth of the U.S. economy.

But anticipating what you were about to say, Rachel, speaking of the giant consolidation in the health industry by UnitedHealth, I am not the only one, we are not the only ones who have noticed. The Wall Street Journal reported this week that the Justice Department has begun an antitrust investigation of said UnitedHealthcare, which provides not only health insurance and claims processing services like those from Change Healthcare, but also through its subsidiary Optum, owns a network of physician groups, one of the largest pharmacy benefit managers, and provides a variety of other health services. Apparently one question investigators are pursuing is whether United favors Optum-owned groups to the detriment of competing doctors and providers.

I think my question here is what took so long? I know that the Justice Department looked at it when United was buying Change Healthcare, but then they said that was OK.

Cohrs: Yeah. I will say I think this is a great piece of reporting here, and these are excellent questions about what happens when the vertical integration gets to this level, which we just really haven’t seen with UnitedHealthcare, where they’re aggressively acquiring provider clinics. I think it was a home health care company that they were trying to buy as well.

So I think it is interesting because now that the acquisitions have happened on some of these, there will be evidence and more material for investigators to look at. It won’t be a theoretical anymore. So I will be interested to see just how this plays out, but it does seem like the questions they’re asking are pretty wide-ranging, certainly related to providers, but also related to an MLR [medical loss ratio]. What if you own a provider that’s charging your insurance company? How does that even work and what are the competitive effects of that for other practices? So I think …

Rovner: And MLRs, for those who are not jargonists, it’s minimum loss ratios [also known as medical loss ratio], and it’s the Affordable Care Act requirement that insurers spend a certain amount of each dollar on actual care rather than overhead and profit and whatnot. So yeah, when you’re both the provider and the insurer, it’s kind of hard to figure out how that’s going.

I am sort of amazed that it’s taken this long because United has been sort of expanding geometrically for the last decade or so.

Kenen: It’s sort of like the term vertical integration, which is the correct term that Rachel used, but as she said that, I sort of had this image of a really tall, skinny, vertical octopus. There’s more and more and more things getting lumped into these big, consolidating, enormous companies that have so much control over so much of health care and concentrated in so few hands now. It’s not just United. I mean, they’re big, but the other big insurers are big too.

Cohrs: Right. I did want to also mention just that we’re kind of seeing this play out in other places too, like Eli Lilly creating telehealth clinics to prescribe their obesity medications. Again, there’s no evidence that they’re connected to this in any way, but I think it is going to be a cautionary tale for other health care companies who are looking into this model and asking themselves, “If UnitedHealthcare can do it, why can’t we do it?” It will be interesting to see how this plays out for the rest of the industry as well.

Rovner: Yeah, when I started covering health policy, I never thought I was going to become a business reporter, but here we are.

Moving on to “This Week in Health Misinformation,” we have Joanne, or rather an interesting, and as it turns out, extremely timely story about vaccines that Joanne wrote for Politico Magazine. Joanne, tell us your thesis here with this story.

Kenen: I wanted to look at how much the public health and clinician community had learned about combating misinformation, sort of a real-life, real-time unfolding before our eyes, which was the rollout of the RSV vaccine.

And I think the two big takeaways, I mean, it’s a fairly … I guess there were sort of three takeaways from that article. One, is they’ve learned stuff but not enough.

Two, is that it’s not that there was this huge campaign against the RSV vaccine, there is misinformation about the RSV vaccine, but basically it just got subsumed into this nonstop, ever-growing anti-vaccine movement that you didn’t have to target RSV. Vaccines is a dirty word for a section of the population.

And the third thing I learned is that the learning about fighting disinformation, the tools we have, you can learn about those tools and deploy those tools, but they don’t work great. There’ve been some studies that have found that what they call debunking or fact-checking, teaching people that what they believe is untrue, that they say, “Ah, that’s not right,” and then a week later they’re back to their original, as little as one week in some studies. One week, you’re back to what you originally thought. So we just don’t know how to do this yet. There are more and more tools, but we are not there.

Rovner: Well, and I say this story is timely because we’re looking at a pretty scary measles outbreak in Florida and a Florida surgeon general who has rejected all established public health advice by telling parents it’s up to them whether to send their exposed-but-unvaccinated children to school rather than keep them home for the full 21 days that measles can take to incubate.

The surgeon general has been publicly taken to task by, among others, Florida’s former surgeon general. I can remember several measles outbreaks over the years, often in less-than-fully-vaccinated communities, but I can’t remember any public health officials so obviously flouting standard public health advice.

Joanne, have you ever seen anything like this?

Kenen: No. It’s like his public stance is like, “Measles, schmeasles.” It’s like a parent has the right to decide whether they’re potentially contagious, goes to school and infects other children, some of whom may be vulnerable and have health problems. It is this complete elevation of medical liberty or medical freedom completely disconnected to the fact that we are connected to one another. We live in communities. We supposedly care about one another. We don’t do a very good job of that, and this is sort of the apotheosis of that.

Rovner: And one of the main reasons that public schools require vaccines is not just for the kids themselves, but for kids who may have younger siblings at home who are not yet fully vaccinated. That’s the whole idea behind herd immunity, is that if enough people are vaccinated then those who are still not fully vaccinated will be protected because it won’t be floating around. And obviously in Florida, measles, which is, according to many doctors, one of the most contagious diseases on the planet, is making a bit of a comeback. So it is sort of, as you point out, kind of the end result of this demonization of all vaccines.

Kenen: And our overall vaccination rate for childhood immunization has dropped and it’s dropped, I’d have to fact-check myself, I think what you need for herd immunity is 95% and it’s …

Rovner: I think it’s over 95.

Kenen: And that we’re down to maybe 93[%]. I mean, this number was in that article that I wrote, but I wrote it a few weeks ago and I may be off by a percentage point, so I want to sort of clarify that nobody should quote me without double-checking that. But basically, we’re not where we need to be and we’re not where we were just a few years ago.

Rovner: Another space we will continue to watch.

Well, that is this week’s news. Now we will play my interview with law professor Greer Donley, and then we will come back and do our extra credits.

I am thrilled to welcome to the podcast, Greer Donley, associate dean for research and faculty development and associate professor of law at the University of Pittsburgh Law School. She’s an expert in legal issues surrounding reproductive health in general and abortion in particular, and someone whose work I have regularly relied on over the past several years, so thank you so much for joining us.

Greer Donley: I’m so happy to be here. Thanks for having me.

Rovner: So I’ve asked you here to talk about how an anti-abortion president could use an 1873 law called the Comstock Act to basically ban abortion nationwide. But first, because it is still so in the news, I have to ask you about the controversy surrounding the Alabama Supreme Court’s ruling that frozen embryos for in vitro fertilization are legally children. Do you think this is a one-off, or is this the beginning of states really, fully embracing the idea of personhood from the moment of fertilization?

Donley: Man, I have a lot to say about that. So I’ll start by saying that first of all, this is the logical extension of what people have been saying for a long time about, “If life starts at conception, this is what that means.” So in some sense, this is one of those things where people say, “Believe people when they tell you something.” Folks have been saying forever, “Life starts at conception.” This is a logical outgrowth of that. So in some sense, it’s not particularly surprising.

It’s also worth noting that states have been moving towards personhood for decades, often through these kind of state laws, like wrongful death, which is exactly what happened here. So this is the first case that found that an embryo outside of a uterus was a children for this purpose of wrongful death, but many states had been moving in the direction of finding a fetus or even an embryo that’s within a pregnant person to be a child for the purpose of wrongful death for a while now. And that has always been viewed as the anti-abortion movement towards personhood. In some sense, this is just kind of the logical outgrowth, the logical extension, of the personhood movement and the permission that Dobbs essentially gave to states to go as far as they wanted to on this question.

So whether or not this is going to be the beginning of a new trend is, I think, in my mind, going to be really shaped by public backlash to the Alabama decision, particularly. I think that many folks within the anti-abortion movement, again, they mean what they say. They do believe that this is a life and it should be treated as any other life, but whether or not they are going to perceive this as the ideal political climate in which to push that agenda is another question.

And my personal view is that, given the backlash to the Alabama Supreme Court, you might see folks retreating a little bit from this. I think we’re starting to see a little bit of that, where more moderate people within the Republican Party are going to say, “This is not the moment to go this far,” or maybe even, “I’m not sure I actually support this logical outgrowth of my own opinion,” and so we’re going to have to kind of …

Rovner: “I co-sponsored this bill, but I didn’t realize that’s what it would do.”

Donley: Exactly. Right? So we’re going to, I think, really have to see how people’s views change in response to the backlash.

Rovner: Let us go back to Comstock. Who was this person, Anthony Comstock? What does this law do and why is it still on the books 151 years after it was passed?

Donley: Ugh, yes, OK. So Anthony Comstock, he is what people often call, “The anti-vice crusader.” This law passed in 1873. It’s actually a series of laws, but we often compile them and call them the Comstock Act.

The late 1800s were a moment of change, where many people in this country were for the first time being exposed to the idea that abortion is immoral for religious reasons. Before that for a long time, in the early 1800s, people regularly purchased products to try to what they call, “Bring on the menses,” or menstrual regulation. So it was not uncommon. It was a fairly commonly held view up until late 1800s that the pregnancy was nothing until it was a quickening, there was a quickening where the pregnant person felt movement.

So Comstock was one of the people who was really kind of a part of changing that culture in the late 1800s, and he had the power as the post office inspector of investigating the mail throughout our country. So he was influential not only in helping to pass a law that made it illegal to ship through interstate commerce all sorts of things that he considered immoral, which explicitly included abortion and contraception, but also used vague terms like “anything immoral.” And he was the person that was then in charge of enforcing those laws by actually investigating the mail. His investigations led to pretty horrible outcomes, including many people killing themselves after he started investigating them for a variety of Comstock-related crimes at the time.

So obviously, this law was passed before women had the right to vote, in a completely different time period than we exist today, and it really remained on the books by an accident of history, in my mind.

So in the early 1900s, there was a series of cases. This was the moment where we particularly saw a huge movement towards birth control. So as that movement was going on, you saw a lot of litigation in the courts that were interpreting the Comstock laws related to contraception, finding that it had to be narrowly limited to only unlawful contraception or unlawful abortion. Because the Comstock laws, by its terms, which this should shock everybody who’s hearing me, has literally no exceptions, not even for the life of the pregnant person. And it is so broad that it would ban abortion nationwide from the beginning of a pregnancy without exception. Procedural abortion, pills, everything.

Rovner: And people think of this as the U.S. mail, but it’s not just the U.S. mail. It’s basically any way you move things across state lines, right?

Donley: Right. Because we live in a national economy now, so there’s nothing in medicine that exists in a purely intrastate environment. So every abortion provider in the country is dependent on them and their state mail to get things that they need for procedural abortion and pills.

In the early to mid-1900s, right around the 1930s, there was a series of cases that said this law only applied for unlawful contraception and abortion because they had to read that term into the law. Eventually in the late 1930s, you saw the federal government stop enforcing it completely. And then you had the constitutional cases came out that found a right to contraception and abortion, and so the law was presumed unconstitutional for half a century. No one was repealing it because everyone assumed that it was never going to come back to life. In comes Dobbs, in come the modern anti-abortion movement, and now we are here.

Rovner: Yeah. So how could a President Trump, if he returns to the White House, use this to ban abortion nationwide?

Donley: Yes, because this law was never repealed, and because the case that presumptively made it unconstitutional, Roe v. Wade, and the cases that came after that, are now no longer good law, presumptively the law, like a zombie, comes back to life.

And so the anti-abortion movement is now trying to reinterpret the law, right? We’re talking about such a long period of time and all those 1930s cases, since that time period, you have the rise of what we call textualism, which is a theory of statutory interpretation that really likes to stick to the text. That was something that’s been around for a while, but in modern jurisprudence, that has become increasingly important, and the anti-abortion movement sees, “Well, all these judges are now textualists, and we can say this law is still good. By its clear terms, it bans shipping through interstate commerce anything that could be used for an abortion. Voila. We have our national abortion ban without having to get a single vote in Congress. All we need is a Republican president that will enforce the law as it’s written and on the books today,” and that is their theory.

Rovner: And that’s included, I think, in one of the briefs that was filed today in the abortion pill case, right?

Donley: Absolutely. In that case, that’s a case concerning the regulation of mifepristone, one of the abortion pills, that’s before the Supreme Court this summer. You had parties saying, “The law is clear and it is as broad as it’s written,” essentially.

Rovner: Well, this doesn’t apply to contraception anymore, right?

Donley: Right. So right after the Supreme Court case Griswold [v. Connecticut], which found a constitutional right to contraception, but before Roe, you had the Congress actually repealed the portion of Comstock related to contraception. But again, it was before Roe, so they didn’t repeal the part related to abortion, and then Roe came in and made that part presumptively unconstitutional.

Of course, going back in time, we would say, “You got to repeal that law. You have no idea what the future may be,” but I don’t think people really saw this moment coming. They should have. We should have all been preparing for this more. But, yeah.

Rovner: One of the things that I don’t think I had appreciated until I read the op-ed that you co-wrote, thank you very much, is that there could be a reach-back here. It’s not even just abortions going forward, right?

Donley: Right. So the idea here is that, generally, laws have a statute of limitations, right? So you could potentially have a President Trump come in, say that he’s going to start enforcing this law immediately, and even if the second Jan. 1 comes, people stop shipping anything through interstate commerce, he could still go back and say, “Well, the statute of limitations is five years.” So you go back in time for five years and potentially bring charges against someone.

So one of the important pieces of advocacy that we might have in this moment is to really encourage President Biden, if he were to not win the election, to preemptively essentially pardon anybody for any Comstock-related crimes to make sure that that can’t be used against them. That’s a power he actually has and will be a very important power for him to use in that instance. But it’s quite alarming how Comstock could be used in this period, but also retrospectively.

Rovner: Last question, and I know the answer to this, but I think I need to remind listeners, if Congress doesn’t have to pass anything to implement a nationwide ban, why haven’t previous anti-abortion Republican presidents tried to do this?

Donley: While Roe and [Planned Parenthood of Southeastern Pennsylvania v.] Casey were good law, there was no way that they could possibly do that. It would’ve been unconstitutional for them to try to criminalize people for exercising their constitutional right to reproductive health care for abortion. So we’re really in a new moment where essentially the Supreme Court overturned those cases while President Biden was in office, and so the real question is whether a Republican administration could come in and change everything.

Rovner: We shall see. Greer Donley, thank you so much for coming to explain this.

Donley: Thank you for having me.

Rovner: OK, we are back. It’s time for our extra-credit segment. That’s when we each recommend a story we read this week we think you should read, too. As always, don’t worry if you miss it. We will post the links on the podcast page at kffhealthnews.org and in our show notes on your phone or other mobile device.

Rachel, you were the first to choose this week. Why don’t you go first?

Cohrs: The article I chose is in The New York Times. The headline is “$1 Billion Donation Will Provide Free Tuition at a Bronx Medical School” by Joseph Goldstein. And it’s about how this 93-year-old widow of an early investor in Berkshire Hathaway has given $1 billion to a medical school in the Bronx to pay for students’ tuition. And I think her idea behind it is that it will open up the pool of students who might be able to go to medical school. I imagine applications might increase to this school as well. And she was a professor at the school during her career as well.

To me, it’s not a scalable solution necessarily for the cost of medical education, but I think it does highlight how broke everything is. When we’re talking about Medicare payment to doctors, I think one of the arguments they always use is doctors have debt and there’s inflation and costs have gone up so much, and I think the cost of education in this country certainly is one factor in that, that it’s really hard to address from a simply health care policy standpoint.

So I think not necessarily a scalable solution, but will definitely make a difference in a lot of students’ lives and just give them more freedom to practice in the specialty that they might want to, which we all know we need more primary care doctors and doctors in a variety of different settings. So I think it’s a rare piece of good news.

Rovner: Yeah, it might not be scalable, but it’s not the first, which is kind of … I remember, in fact, NYU is now having a no-tuition medical school. UCLA, although I think UCLA is only for students who can demonstrate financial need. But in doing those earlier stories, and I have not updated this, at the time, which is a couple of years ago, the average medical student debt graduating is over $250,000. So you can see why they feel like they need to be in more lucrative specialties because they’re going to be paying their student loans back until they’re in their 40s, most of them. This is clearly a step in that direction.

Riley, why don’t you go next?

Griffin: Yeah. I wanted to share a story that I’ve been fairly obsessed with over the last month. It’s one of my own. It’s “US Seeks to Limit China’s Access to Americans’ Personal Data.” This week, the Biden administration announced that it is issuing, or has at this point issued, an executive order to secure Americans’ sensitive personal data, and we broke this story about a month ago.

Why it is so interesting to the health world is, one of the key parts that was a motivating factor in putting together this executive order, is DNA, genomic data. The U.S., the National Security Council, our national security apparatus is really concerned about what China and other foreign adversaries are doing with our genetic information. And we can get more into that in the story itself, but it is fascinating, and now we’re seeing real action to regulate and protect and ensure that that bulk data doesn’t get into the hands of people who want to use it for blackmail and espionage.

Rovner: Yeah, it was super scary, I will say. Joanne?

Kenen: I couldn’t resist this one. It’s in Axios. It’s by Tina Reed, and the headline is “An Unexpected Finding Suggests Full Moons May Actually Be Tough on Hospitals.” Caveat, before I go on, there is research out there that proves what I’m about to say is wrong.

But anyway, a company that makes panic buttons, so a hospital security company that one of the things they do is provide panic buttons, they did a study of how and when these panic buttons are used, and they found they go up during full moons. And they also found that other things rise during full moons. GI [gastro-intestinal] disorders go up, ambulance rides connected to motor vehicle accidents go up, and psychiatric admissions go up. So maybe that research that I cited at the beginning saying this is hogwash needs to be reevaluated in some subcategories.

Rovner: There’s always new things to find out in science.

My extra credit this week is from ProPublica. It’s called “Their States Banned Abortion. Doctors Now Say They Can’t Give Women Potential Lifesaving Care,” by Kavitha Surana. It’s another in a series of stories we’ve seen about women with serious pregnancy complications that are not immediately life-threatening, but who nevertheless can’t get care that their doctors think they need.

This story, however, is written from the point of view of the doctors, specifically members of an abortion committee at Vanderbilt Hospital in Nashville who are dealing with the Tennessee ban that’s one of the strictest in the nation. It’s really putting doctors in an almost impossible position in some cases, feeling that they can’t even tell patients what the risks are of continuing their pregnancies for fear of violating that Tennessee law. It’s a whole new window into this story that we keep hearing about and a really good read.

OK. That is our show. As always, if you enjoy the podcast, you can subscribe wherever you get your podcasts. We’d appreciate it if you left us a review. That helps other people find us too. Special thanks as always to our very patient technical guru, Francis Ying, and our editor, Emmarie Huetteman.

As always, you can email us your comments or questions. We’re at whatthehealth@kff.org, or you can still find me hanging around at Twitter, @jrovner, or @julierovner at Bluesky and @julie.rovner at Threads.

Joanne, where are you hanging these days?

Kenen: Mostly at Threads, @joannekenen1. I still occasionally use X, and that’s @JoanneKenen.

Rovner: Riley, where can we find you on social media?

Griffin: You can find me at X @rileyraygriffin.

Rovner: And Rachel?

Cohrs: I’m at X @rachelcohrs and on LinkedIn more these days, so feel free to follow me there.

Rovner: There you go. We’ll be back in your feed next week. Until then, be healthy.

Credits

Francis Ying
Audio producer

Emmarie Huetteman
Editor

To hear all our podcasts, click here.

And subscribe to KFF Health News’ “What the Health?” on SpotifyApple PodcastsPocket Casts, or wherever you listen to podcasts.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

1 year 1 month ago

Courts, Multimedia, States, Abortion, Alabama, Florida, Health IT, Idaho, KFF Health News' 'What The Health?', Misinformation, Podcasts, U.S. Congress, Women's Health

Pages